This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.
Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period.
Protocol Amendment History
13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2025-10-31; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting2025-11-21